Hepatocellular carcinoma (HCC) is one of the most refractory
cancers. The mechanisms by which
hypoxia further aggravates therapeutic responses of advanced HCC to anticancer drugs remain to be clarified. Here, we report that
hypoxia (1% O2) caused 2.55-489.7-fold resistance to 6 anticancer drugs (
sorafenib,
5-fluorouracil [5-FU],
gemcitabine,
cisplatin,
adriamycin and
6-thioguanine) in 3 HCC cell lines (BEL-7402, HepG2 and SMMC-7721). Among the 6 drugs,
sorafenib, the sole one approved for HCC
therapy, inhibited proliferation with little influence from
hypoxia and displayed the smallest variation among the 3 HCC cell lines tested. By contrast, the inhibition of proliferation by
5-FU, which has been extensively tested in clinical trials but has not been approved for HCC
therapy, was severely affected by
hypoxia and showed a large variation among these cell lines. In 5-FU-treated HCC cells,
hypoxia reduced the levels of basal
thymidylate synthase (TS) and functional TS, leading to decreased
dTMP synthesis and DNA replication.
Hypoxia also affected the accumulation of FdUTP and its misincorporation into
DNA. Consequently, both single-strand breaks and double-strand breaks in
DNA were reduced, although
hypoxia also inhibited DNA repair. In 5-FU-treated HCC cells,
hypoxia further abated S-phase arrest, alleviated the loss of mitochondrial membrane potential, diminished the activation of
caspases, and finally resulted in reduced induction of apoptosis. Thus,
hypoxia induces universal but differential drug resistance. The extensive impacts of
hypoxia on the anticancer mechanisms of
5-FU contributes to its
hypoxia-induced resistance in HCC cells. We propose that
hypoxia-induced drug resistance and interference of
hypoxia with anticancer mechanisms could be used as candidate
biomarkers in selecting and/or developing anticancer drugs for improving HCC
therapy.